| Group comparison . | Estimatea . | P valueb . |
|---|---|---|
| CIRC0196 (Fig. 5 ) full modelc: days 42–84 after engraftment | ||
| No Tx vs. CMV | 0.39 | 0.228 |
| No Tx vs. HST | 0.34 | 0.346 |
| No Tx vs. HST-NG | 0.52 | 0.046 |
| CIRC0196 (Fig. 5 ) restricted modeld: days 42–56 after engraftment | ||
| No Tx vs. CMV | 0.37 | 0.061 |
| No Tx vs. HST | 0.94 | 0.005 |
| No Tx vs. HST-NG | 0.75 | <0.001 |
| WWH004 (Fig. 8 ) full modelc: days 51–99 after engraftment | ||
| No Tx vs. CMV-NG | 0.36 | 0.504 |
| No Tx vs. HST-NG | 0.80 | 0.170 |
| WWH004 (Fig. 8 ) restricted modeld: days 51–65 after engraftment | ||
| No Tx vs. CMV-NG | 0.26 | 0.603 |
| No Tx vs. HST-NG | 0.31 | 0.538 |
| Group comparison . | Estimatea . | P valueb . |
|---|---|---|
| CIRC0196 (Fig. 5 ) full modelc: days 42–84 after engraftment | ||
| No Tx vs. CMV | 0.39 | 0.228 |
| No Tx vs. HST | 0.34 | 0.346 |
| No Tx vs. HST-NG | 0.52 | 0.046 |
| CIRC0196 (Fig. 5 ) restricted modeld: days 42–56 after engraftment | ||
| No Tx vs. CMV | 0.37 | 0.061 |
| No Tx vs. HST | 0.94 | 0.005 |
| No Tx vs. HST-NG | 0.75 | <0.001 |
| WWH004 (Fig. 8 ) full modelc: days 51–99 after engraftment | ||
| No Tx vs. CMV-NG | 0.36 | 0.504 |
| No Tx vs. HST-NG | 0.80 | 0.170 |
| WWH004 (Fig. 8 ) restricted modeld: days 51–65 after engraftment | ||
| No Tx vs. CMV-NG | 0.26 | 0.603 |
| No Tx vs. HST-NG | 0.31 | 0.538 |
Estimate comparing log10-transformed VLs between groups.
Adjusted for multiple comparisons using multivariate t-distribution method. Bolded P value denotes significance.
Modeling longitudinal VLs from peak viremia to end of study.
Modeling longitudinal VLs from peak viremia to point of viral escape.